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Abstract
Objective
To examine whether prospective bleeding risk
estimates for patients undergoing percutaneous
coronary intervention could improve the use of
bleeding avoidance strategies and reduce bleeding.
Design
Prospective cohort study comparing the use of
bleeding avoidance strategies and bleeding rates
before and after implementation of prospective risk
stratification for peri-procedural bleeding.
Setting
Nine hospitals in the United States.
Participants
All patients undergoing percutaneous coronary
intervention for indications other than primary
reperfusion for ST elevation myocardial infarction.
Main outcome measures
Use of bleeding avoidance strategies, including
bivalirudin, radial approach, and vascular closure
devices, and peri-procedural bleeding rates, stratified
by bleeding risk. Observed changes were adjusted for
changes observed in a pool of 1135 hospitals without
access to pre-procedural risk stratification. Hospital
level and physician level variability in use of bleeding
avoidance strategies was examined.
Results
In a comparison of 7408 pre-intervention procedures
with 3529 post-intervention procedures, use of

What is already known on this topic
Bleeding is one of the most common complications of percutaneous coronary
intervention (PCI)
Valid models to estimate patients’ risks of bleeding have been developed
Bleeding avoidance strategies can reduce bleeding but are paradoxically applied to
patients with the lowest risk of bleeding, resulting in inefficient and less effective
treatment than could be obtained by preferentially treating higher risk patients

What this study adds
After provision of patients’ individualized estimates of risk before PCI, bleeding
avoidance strategies were preferentially increased in those at higher risk of
bleeding and the odds of bleeding were reduced by 44%
Marked variability existed in how individual operators treated patients, on the basis
of their risk of bleeding, both before and after the provision of patients’ bleeding
risks
An opportunity exists to improve the consistency of bleeding avoidance
management to further improve the safety of PCI
the bmj | BMJ 2015;350:h1302 | doi: 10.1136/bmj.h1302

bleeding avoidance strategies within intervention sites
increased with pre-procedural risk stratification (odds
ratio 1.81, 95% confidence interval 1.44 to 2.27),
particularly among higher risk patients (2.03, 1.58 to
2.61; 1.41, 1.09 to 1.83 in low risk patients, after
adjustment for control sites; P for interaction=0.05).
Bleeding rates within intervention sites were
significantly lower after implementation of risk
stratification (1.0% v 1.7%; odds ratio 0.56, 0.40 to
0.78; 0.62, 0.44 to 0.87, after adjustment); the
reduction in bleeding was greatest in high risk
patients. Marked variability in use of bleeding
avoidance strategies was observed across sites and
physicians, both before and after implementation.
Conclusions
Prospective provision of individualized bleeding risk
estimates was associated with increased use of
bleeding avoidance strategies and lower bleeding
rates. Marked variability between providers highlights
an important opportunity to improve the consistency,
safety, and quality of care.
Study registration
Clinicaltrials.gov NCT01383382.

Introduction
Most medical treatments are associated with heterogeneity of benefit; some patients benefit a great deal from
treatment, whereas others do not.1 2 Observational studies show many examples of a “risk-treatment paradox,”
in which patients at the highest risk (and with the greatest potential to gain from treatment) are treated less
often than those at lower risk and with less potential to
benefit.3–10 These practice patterns are not patient centered and are intrinsically inefficient in terms of costs,
safety, and outcomes. Developing methods to integrate
individualized risk stratification within routine clinical
care has the potential to remedy this paradoxical practice pattern by alerting clinicians to each patient’s
potential benefits from treatment and enabling more
patient centered, evidence based, efficient care with
safer, better outcomes.11
The use of bleeding avoidance strategies at the time
of percutaneous coronary intervention is a prototypical
example of the risk-treatment paradox. Bleeding is one
of the most common non-cardiac complications of percutaneous coronary intervention and is associated with
increased mortality, morbidity, and costs.12–19 It is also
modifiable through the use of bleeding avoidance strategies, such as bivalirudin, radial percutaneous coronary
1
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intervention, and, potentially, vascular closure
devices.20–25 Importantly, although the magnitude of
bleeding reduction and bleeding related mortality are
strongly associated with patients’ underlying risk of
bleeding,19 22 bleeding avoidance strategies are paradoxically used most often in patients at low risk of
bleeding and least often in those at high risk.22
To improve use of bleeding avoidance strategies, and
reduce percutaneous coronary intervention related
bleeding, we implemented a novel method for prospectively determining and informing physicians of
patients’ bleeding risks by using a validated risk model
developed by the American College of Cardiology’s
National Cardiovascular Data Registry (NCDR) CathPCI
Registry.26 Patients’ personalized risks were calculated
with the Patient Risk Information Services Manager
(ePRISM),27–29 which was designed to translate multivariable risk models, using each patient’s specific clinical risk factors, at the point of care. As a vehicle to
translate models to the clinical setting, ePRISM was
designed to be seamlessly integrated within routine
clinical workflow. In the setting of percutaneous coronary intervention, ePRISM was used to generate personalized consent forms and replace sites’ traditional
consent forms, where it has recently been shown to
improve patients’ experience with care.30 It also created
streamlined decision support tools that could be
printed and given to physicians before the percutaneous coronary intervention procedure.
We did a pre/post-implementation study at nine large
US percutaneous coronary intervention centers and
evaluated changes in use of bleeding avoidance strategies and bleeding outcomes, while correcting for contemporary trends among matched NCDR CathPCI
hospitals that did not have access to the ePRISM tool.
We hypothesized that prospective stratification of
bleeding risk could improve the use of bleeding avoidance strategies in higher risk patients and reduce bleeding in patients undergoing percutaneous coronary
intervention.

Methods
In this prospective cohort study, individualized bleeding
risk estimates were incorporated into the informed consent document for all patients undergoing non-emergent coronary angiography (supplemental figure A) and
possible percutaneous coronary intervention at nine US
centers (Washington University, Saint Louis, MO; Integris Hospital, Oklahoma, OK; Yale University, New Haven,
CT; Henry Ford Hospital, Detroit, MI; Baystate Medical
Center, Springfield, MA; The Heart Hospital at Baylor,
Plano, TX; Kaiser Hospital, San Francisco, CA; St John’s
Hospital, Springfield, IL; Mayo Clinic, Rochester, MN).
The pre-procedural risk models were generated using
the ePRISM software platform (Health Outcomes Sciences, Overland Park, KS), which was provided through
grant funding to each center. We compared use of bleeding avoidance strategies and bleeding rates before and
after implementation of the personalized risk estimates.28 29 Because the routine process of care was
changed at each center to include the new personalized
2

consent forms, randomization of individual patients
was not feasible. To overcome the most important bias
in pre-/post-intervention comparisons—namely, temporal trends in care that could account for observed
changes in treatment and outcomes—we used an additional comparison of non-participating NCDR sites as
concurrent controls. This study design (supplemental
figure B) was endorsed by two peer reviewed study sections (American Heart Association and the National
Heart Lung and Blood Institute), who provided funding
for the study.
The implementation of ePRISM has been previously
described,27 31 and a rolling enrollment of sites led to
staggered start dates between March 24, 2010 and May
5, 2011. Before implementation of the new consent process, a study investigator (JAS) provided didactic education about the bleeding risk model and data on the
comparative effectiveness of bleeding avoidance strategies in reducing bleeding. Within one to two months of
implementation, an interventional cardiologist (AKC)
provided additional information on strategies to reduce
bleeding as a function of risk. We considered the period
between the start of prospective risk stratification and
the interventionalist’s visit to be a “break-in” period
and excluded it from analysis. We did not provide
bleeding avoidance strategy protocols to the sites, and
each site was able to implement the tool as fit best
within their practice.
Data from all percutaneous coronary interventions
performed during the study period were available for
analysis through access to each site’s CathPCI Registry
data. The CathPCI Registry, sponsored by the American
College of Cardiology Foundation and the Society for
Cardiovascular Angiography and Interventions, collects detailed clinical characteristics, treatments, and
outcomes using standardized definitions (www.ncdr.
com/webncdr/cathpci/home/datacollection).
The pre-implementation period consisted of the 12
months before implementation of prospective bleeding
risk stratification at each site. The post-implementation
period consisted of the time period after system activation and a physician site visit for didactic education on
the methods and approach to risk stratification. Data
collected in the “break-in” period between implementation and the physician site visit were excluded from
analysis.

Study population
During the study period, 218 physicians across the nine
sites performed 22 066 percutaneous coronary intervention procedures. Patients were excluded from analysis
for the following reasons: ST elevation myocardial
infarction or other emergent procedures for which
insufficient time was available to provide the personalized consent form (n=3895); repeat percutaneous coronary intervention during the same hospital admission
for which attribution of which procedure was associated with bleeding is difficult (n=268); procedures of
unknown status (emergent or other; n=33); procedures
for which the percutaneous coronary intervention operator was not documented (n=274); procedures during
doi: 10.1136/bmj.h1302 | BMJ 2015;350:h1302 | the bmj
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the “break-in” period between implementation and the
physician site visit (n=1470); and procedures in the
post-implementation period for which a personalized
consent with bleeding risk was not generated (n=3156;
for example, a consent had already been signed at a
referring institution, administrative error). We excluded
an additional 2033 procedures from analysis owing
to non-overlapping propensity scores between pre-
implementation and post-implementation groups
(see below). This resulted in a final study cohort of
10 937 percutaneous coronary intervention procedures
(7408 before implementation and 3529 after implementation) performed by 137 physicians.

Bleeding risk estimates
The previously validated CathPCI Registry bleeding risk
model incorporates nine pre-procedural clinical variables (age, sex, previous heart failure, glomerular filtration rate, peripheral vascular disease, previous
percutaneous coronary intervention, functional status,
ST elevation myocardial infarction/non-ST elevation
myocardial infarction, and cardiogenic shock; C statistic=0.72).26 Patients were classified as having low (<1%),
moderate (1–3%), or high (>3%) risk of bleeding. We
selected these cut-off values a priori on the basis of previous publications.22 Because the physicians’ education
components of the intervention encouraged use of
bleeding avoidance strategies in patients at moderate
or high risk for bleeding, the categorical analyses of
bleeding outcomes and changes in bleeding avoidance
strategy use are between patients with low and moderate/high risk (<1% v ≥1%) for bleeding. We calculated
these risk estimates retrospectively for the pre-implementation period by using NCDR data, but they were
not available to the physician before percutaneous coronary intervention.
Outcomes
Study outcomes included use of bleeding avoidance
strategies and in-hospital, post-procedural bleeding
rates. Bleeding avoidance strategies were analyzed
individually and by use of any strategy. Use of bivalirudin was considered the most modifiable strategy, as
radial approaches are very operator dependent (interventionalists tend to predominantly use or not use this
access approach) and the benefits of vascular closure
devices to prevent bleeding are controversial.32 Bleeding events were prospectively collected and defined
according to standard NCDR definitions (access site,
retroperitoneal, gastrointestinal, genitourinary, or
unknown bleeding within 72 hours after percutaneous
coronary intervention, associated with a drop in hemoglobin of ≥3 g/dL or requiring transfusion, procedural
intervention, or surgery).26
Statistical analyses
To account for contemporary trends in use of bleeding
avoidance strategies and bleeding incidence, we
matched the nine study sites to control hospitals
selected from among the 1135 CathPCI Registry sites not
participating in this study. Hospitals were matched on
the bmj | BMJ 2015;350:h1302 | doi: 10.1136/bmj.h1302

annual percutaneous coronary intervention volume,
teaching status, and the physicians’ average pre-ePRISM
rate for each outcome. Given the number of outcomes,
we could not match intervention sites with controls on
the pre-procedural rates of all five outcomes (bleeding,
bivalirudin use, closure device use, radial access, and
any bleeding avoidance strategy use), so we did separate
matches for each outcome. To reduce the effects of
measurement error and sampling variation among the
specific control hospitals selected, we used full optimal
matching to match as many controls as possible to each
study site. Between 130 and 178 control hospitals were
matched, depending on the outcome. We ensured
balance between study and matched control hospitals
by calculating standardized differences, which were all
less than 10% for each variable within each outcome
analysis (supplemental table A).
To adjust for differences in patients’ and procedural
characteristics before and after ePRISM implementation,
as well as between study and control sites, we calculated
multiple group propensity scores. This enabled us to
adjust simultaneously for a myriad of patients’ characteristics so that the differences in treatment and outcomes were attributable to the intervention rather than
to the types of patients treated in the different time periods. To do this, we constructed a multinomial logistic
regression model predicting membership in each of the
four “treatment” groups (study v control×pre- v postePRISM implementation) on the basis of 31 demographic,
clinical, and procedural variables (table 1). From this
model, we obtained three propensity scores estimating
the probability of membership in each of three groups
compared with the reference group of study sites before
implementation of ePRISM. We assessed covariate balance by comparing propensity adjusted standardized
differences between patients in the pre-intervention and
post-intervention groups (<10% indicates good balance).
Overlap of propensity score distributions among the four
groups was good for all scores. We included these scores
as covariates in the outcome models.
The primary unit of analysis in this study was the percutaneous coronary intervention physician operator. We
used hierarchical logistic regression models to assess
the effect of exposure to ePRISM on physicians’ change
in use of bleeding avoidance strategies and the incidence of post-procedural bleeding, corrected for concurrent trends among control hospitals. Models included a
fixed effect for study phase (before v after ePRISM implementation, centered within physician), physician level
random intercepts and random effects for study phase,
a fixed effect for study versus control hospital groups, a
study phase-by-group interaction term, and adjustment
for hospital matched sets and the three logit propensity
scores. We quantified the effect of ePRISM as the relative
difference in odds ratio for study phase between study
and control hospitals. In addition, among the nine study
sites, we evaluated variability in use of bleeding avoidance strategies by physician with median odds ratios,
which estimate the relative difference in use between
two randomly selected physicians or hospitals for “identical” patients with the same covariates.
3
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Table 1 | Baseline characteristics of patients. Values are numbers (percentages) unless
stated otherwise
Characteristic

Mean (SD) age, years
Male sex
Non-white ethnicity
No insurance
Admission source:
Emergency department
Transfer in from another acute care facility
Other
Mean (SD) body mass index, kg/m2
Family history of premature coronary artery disease
Dyslipidemia
Hypertension
Diabetes
Previous myocardial infarction
Previous PCI
Previous coronary artery bypass graft
Peripheral arterial disease
Cerebrovascular disease
Chronic heart failure
Previous valve surgery/procedure
Chronic lung disease
On dialysis
Mean (SD) glomerular filtration rate, mL/min/1.73 m2
Mean (SD) pre-procedure hemoglobin, g/dL
Heart failure in previous 2 weeks
Cardiomyopathy or left ventricular systolic dysfunction
Cardiogenic shock in previous 24 hours
Cardiac arrest in previous 24 hours
Stress or imaging studies
Coronary artery disease presentation:
Asymptomatic
Symptom unlikely to be ischemic
Stable angina
Unstable angina
NSTEMI
Anginal classification in previous 2 weeks:
No symptoms
CCS class I
CCS class II
CCS class III
CCS class IV
PCI status:
Elective
Urgent
PCI indication:
High risk NSTEMI or unstable angina
Staged PCI
Other
Bleeding risk:
Low (0 to <0.01)
Moderate (0.01 to <0.03)
High (≥0.03)

Standard
consent*
(n=7408)

Personalized
consent
(n=3529)

65.7 (11.6)
5158 (69.6)
886 (12.0)
189 (2.6)

66.2 (11.5)
2504 (71.0)
409 (11.6)
64 (1.8)

1158 (15.6)
2368 (32.0)
3868 (52.2)
30.1 (7.4)
2377 (32.1)
6582 (88.8)
6373 (86.0)
2679 (36.2)
2643 (35.7)
3209 (43.3)
1693 (22.9)
988 (13.3)
976 (13.2)
1072 (14.5)
161 (2.2)
950 (12.8)
207 (2.8)
76.1 (27.4)
13.3 (1.8)
632 (8.5)
591 (8.0)
16 (0.2)
23 (0.3)
2956 (39.9)

360 (10.2)
891 (25.2)
2275 (64.5)
30.3 (8.4)
1089 (30.9)
3175 (90.0)
3053 (86.5)
1265 (35.8)
1346 (38.1)
1566 (44.4)
863 (24.5)
567 (16.1)
480 (13.6)
549 (15.6)
65 (1.8)
511 (14.5)
99 (2.8)
75.3 (26.0)
13.4 (1.8)
324 (9.2)
326 (9.2)
6 (0.2)
9 (0.3)
1618 (45.8)

817 (11.0)
73 (1.0)
1565 (21.1)
3083 (41.6)
1867 (25.2)
(n=7390)
871 (11.8)
249 (3.4)
1465 (19.8)
2353 (31.8)
2452 (33.2)

385 (10.9)
38 (1.1)
762 (21.6)
1633 (46.3)
711 (20.1)
(n=3524)
397 (11.3)
108 (3.1)
763 (21.7)
1140 (32.3)
1116 (31.7)

3322 (44.8)
4086 (55.2)

1836 (52.0)
1693 (48.0)

4106 (55.4)
372 (5.0)
2930 (39.6)
(n=7143)
2237 (31.3)
3523 (49.3)
1383 (19.4)

1796 (50.9)
181 (5.1)
1552 (44.0)
(n=3415)
1047 (30.7)
1708 (50.0)
660 (19.3)

P value

0.043
0.575
0.016
<0.001

0.295
0.178
0.091
0.492
0.728
0.012
0.286
0.064
<0.001
0.539
0.142
0.244
0.017
0.974
0.147
0.014
0.278
0.027
0.615
0.615
<0.001
<0.001

0.136

<0.001

<0.001

0.760

CCS=Canadian Cardiovascular Society; NSTEMI=non-ST elevation myocardial infarction;
PCI=percutaneous coronary intervention.
*Without bleeding risk estimates.
†With individual bleeding risk estimates.

Finally, we repeated the above analyses, augmenting
the models with terms for bleeding risk and ePRISM-byrisk interactions, to examine whether greater changes
in treatment or benefit occurred among higher risk
patients. We did separate analyses incorporating
bleeding risk as a categorical (low v moderate/high) or
4

continuous variable. Among the nine study sites, we
derived variability in physicians’ use of bleeding avoidance strategies as a function of bleeding risk both
before and after implementation of ePRISM from the
estimated random effects from the model incorporating
bleeding risk as a continuous variable. We also repeated
these approaches for other anticoagulation and antiplatelet regimens, including unfractionated heparin,
low molecular weight heparin, glycoprotein IIb/IIIa
inhibitors, and thienopyridine use (both clopidogrel
and prasugrel). We also did an exploratory descriptive
analysis to assess the effect of pre-procedural risk stratification on in-hospital mortality, as recorded in the
NCDR registry, among the intervention sites. We used
SAS 9.3 and R version 2.15.0 for all analyses.33 All
hypothesis tests were two tailed and evaluated at a significance level of 0.05.

Results
The mean “break-in” period between implementation
of pre-procedural risk stratification and the physician
site visit was 2.1 months, and the mean study duration
after the physician site visit was 9.4 months (supplemental table B). The final study cohort consisted of
10 937 percutaneous coronary intervention procedures
(7408 before implementation and 3529 after implementation) by 137 physicians. Table 1 shows patients’ baseline demographic and clinical characteristics.
Estimated bleeding risks were similar between the two
groups. After propensity adjustment, all patients’ and
procedural characteristics were well balanced (standardized differences 0–28% before adjustment, 0–7%
after; supplemental table A).
Processes of care to mitigate bleeding
To understand the effect of pre-procedural risk stratification on the use of bleeding avoidance strategies, we
compared the observed changes at the intervention
sites overall, and stratified by bleeding risk, and
adjusted these observations for changes in bleeding
avoidance strategy use at the control sites. Overall
bleeding avoidance strategy use (table 2) increased
from 81.4% to 88.7% after implementation (odds ratio
1.81, 95% confidence interval 1.44 to 2.27; P<0.001). The
increase was significantly greater in patients at high
risk of bleeding (odds ratio 2.03 v 1.48 for low risk
patients; P=0.05 for interaction). After correction for
contemporary trends, the effect of pre-procedural risk
stratification on the use of bleeding avoidance strategies was of borderline statistical significance (corrected odds ratio 1.23, 0.98 to 1.56) across all patients
but significantly greater in patients at high risk for
bleeding (1.41, 1.09 to 1.83; P=0.008). When we examined individual bleeding avoidance strategies, the
availability of pre-procedural bleeding risk estimates
was associated with similar overall use of bivalirudin
(odds ratio 1.18, 0.93 to 1.48) but a change in practice
that favored its use in high risk patients (1.36, 1.05 to
1.75) over low risk patients (0.92, 0.69 to 1.24; P value
for interaction=0.03). When we adjusted for control
hospitals, we found no overall difference in bivalirudin
doi: 10.1136/bmj.h1302 | BMJ 2015;350:h1302 | the bmj
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Table 2 | Bleeding avoidance strategy use and post-percutaneous coronary intervention (PCI) bleeding by bleeding risk and availability of these risks
before PCI
PRISM effect (corrected
for controls)

Study hospitals
Pre-PRISM
rate

Post-PRISM
rate

Outcomes—peri-procedural bleeding
Post-PCI bleeding:
Overall
1.7%
1.0%
Low bleeding risk
0.7%
0.3%
Moderate/high bleeding risk
2.1%
1.3%
Processes of care—bleeding avoidance strategies
Any strategy:
Overall
81.4%
88.7%
Low bleeding risk
85.9%
90.0%
Moderate/high bleeding risk
78.7%
88.3%
Bivalirudin:
Overall
48.6%
52.6%
Low bleeding risk
51.5%
49.6%
Moderate/high bleeding risk
47.9%
55.5%
Closure device:
Overall
31.2%
28.9%
Low bleeding risk
37.4%
33.4%
Moderate/high bleeding risk
29.4%
28.6%
Radial access*:
Overall
4.7%
10.7%
Low bleeding risk
5.6%
14.2%
Moderate/high bleeding risk
4.5%
9.8%

PRISM×risk
interaction
P value

Control hospitals—
odds ratio (95% CI)

Odds ratio (95% CI)

P value

0.71

0.91 (0.84 to 0.98)
0.91 (0.74 to 1.11)
0.90 (0.83 to 0.98)

0.62 (0.44 to 0.87)
0.51 (0.21 to 1.20)
0.65 (0.45 to 0.94)

0.006
0.12
0.02

<0.001
0.02
<0.001

0.05

1.46 (1.38 to 1.55)
1.50 (1.39 to 1.62)
1.44 (1.35 to 1.53)

1.23 (0.98 to 1.56)
0.99 (0.71 to 1.37)
1.41 (1.09 to 1.83)

0.08
0.94
0.008

1.18 (0.93 to 1.48)
0.92 (0.69 to 1.24)
1.36 (1.05 to 1.75)

0.17
0.61
0.02

0.03

1.28 (1.21 to 1.36)
1.27 (1.18 to 1.36)
1.29 (1.31 to 1.27)

0.92 (0.72 to 1.16)
0.73 (0.54 to 0.99)
1.05 (0.81 to 1.37)

0.47
0.04
0.70

0.90 (0.73 to 1.10)
0.84 (0.64 to 1.10)
0.96 (0.77 to 1.20)

0.30
0.20
0.73

0.16

0.94 (0.89 to 0.99)
0.90 (0.84 to 0.96)
0.95 (0.89 to 1.00)

0.96 (0.77 to 1.18)
0.94 (0.71 to 1.24)
1.02 (0.81 to 1.28)

0.67
0.65
0.88

2.45 (1.84 to 3.26)
2.77 (1.90 to 4.02)
2.32 (1.72 to 3.14)

<0.001
<0.001
<0.001

0.46

2.26 (2.03 to 2.51)
2.54 (2.22 to 2.91)
2.36 (2.11 to 2.63)

1.09 (0.80 to 1.47)
1.09 (0.73 to 1.62)
0.99 (0.72 to 1.36)

0.60
0.68
0.93

Odds ratio (95% CI)

P value

0.56 (0.40 to 0.78)
0.46 (0.20 to 1.06)
0.59 (0.41 to 0.85)

<0.001
0.07
0.004

1.81 (1.44 to 2.27)
1.48 (1.08 to 2.04)
2.03 (1.58 to 2.61)

*Among physicians performing at least one radial procedure before implementation of PRISM.

use in high risk patients but decreased use in lower risk
patients (odds ratio 0.73, 0.54 to 0.99; P=0.04). We
found no significant changes in use of vascular closure
devices within intervention sites or between intervention and control sites. Although use of radial access
increased within the intervention sites, these changes
were similar to those at control sites and did not vary
by bleeding risk categories.
Analyses incorporating risk of bleeding as a continuous variable (supplemental figure C) showed significant
increases in use of bleeding avoidance strategies after
the availability of pre-procedural bleeding risk estimates, although interactions between bleeding avoidance strategy use and bleeding risk were not statistically
significant. Other anticoagulation strategies (supplemental table C) also varied after the intervention, including less use of low molecular weight heparin (overall
odds ratio 0.62, 0.52 to 0.75; adjusted odds ratio 0.71, 0.59
to 0.86, with no significant interaction by bleeding risk
group) and less use of glycoprotein IIb/IIIa inhibitors
(0.66, 0.55 to 0.79, with no interaction by bleeding risk
group and no difference after adjustment for contemporary practice in control sites: 0.91, 0.75 to 1.10). We
observed no significant differences in the use of unfractionated heparin or thienopyridines (either clopidogrel
or prasugrel) after pre-procedural risk stratification once
we adjusted for changes in hospitals without access to
pre-procedural bleeding risk estimates.

Bleeding outcomes
Table 2 summarizes the effect of pre-procedural bleeding risk estimates on bleeding. Bleeding complications
the bmj | BMJ 2015;350:h1302 | doi: 10.1136/bmj.h1302

decreased from 1.7% to 1.0% after implementation
(odds ratio 0.56, 0.40 to 0.78; P<0.001), and this effect
persisted after correction for contemporary trends (difference between differences 0.56 v 0.91, P<0.001; corrected odds ratio 0.62, 0.44 to 0.87, P=0.006). Bleeding
complications decreased significantly at intervention
sites, compared with control sites, for patients at high
risk of bleeding (odds ratio 0.65, 0.45 to 0.94; P=0.02)
but not among patients at low risk of bleeding (0.51,
0.21 to 1.20; P=0.12). Analyses incorporating risk of
bleeding as a continuous variable (fig 1) suggested a
greater absolute decrease in bleeding rate as bleeding
risk increased. In contrast to the beneficial effects of
pre-procedural risk stratification on bleeding, we
observed no differences in in-hospital mortality
among the intervention sites (0.37% pre-ePRISM v
0.41% post-ePRISM; P=0.62).

Hospital and physician variability
Significant hospital and physician level variability in
BAS use was present. In the post-implementation
period, use of bleeding avoidance strategies ranged
from 31% to 98%, bivalirudin use ranged from 1% to
96%, vascular closure device use ranged from 3% to
70%, and radial access ranged from 1% to 51% across
hospitals. The effect of pre-procedural bleeding risk
estimates on bleeding avoidance strategy use varied
widely across hospitals (table 3), with hospital specific odds ratios for the use of any strategy ranging
from 0.49 to 2.65 (P=0.006 for differences by hospital),
although the effect of ePRISM on bleeding avoidance
strategy use was greater than 1.0 in seven of nine
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Fig 1 | Unadjusted rates of bleeding before and after
ePRISM implementation, as a function of bleeding risk.
PCI=percutaneous coronary intervention

 ospitals, suggesting that all but two hospitals
h
increased their use of such strategies after being provided with pre-procedural estimates of patients’
bleeding risk. Within hospitals, we also saw substantial variability in bleeding avoidance strategy use by
physicians at each hospital (table 4). The median
odds ratio for any use of any strategy, after adjustment for between hospital differences, was 4.1 when
the personalized consents were used, indicating a
fourfold difference in the probability of any bleeding
avoidance strategy use between two randomly
selected physicians at the same hospital treating
patients with identical bleeding risk and other clinical characteristics. We observed similar variation for
each individual strategy, with bivalirudin use showing the greatest variability. Figure 2 shows the use of
bivalirudin as a function of patients’ bleeding risks,
before and after pre-procedural risk stratification.
This figure emphasizes the wide variability across
physicians, even after personalized estimates of
bleeding were provided. Some physicians never used
bivalirudin, even among the patients at highest risk
for bleeding, whereas others used it in all of their high
risk patients. Physician level performance for other
strategies are shown in supplemental figure D.
Table 3 | Variation in bleeding avoidance strategy (BAS) use and effect of personalized
bleeding risk estimates across hospitals
Range in BAS use

Range in effect of PRISM

Bleeding avoidance strategy

Pre-PRISM

Post-PRISM

Odds ratios

P value

Any strategy
Bivalirudin
Closure device
Radial access

13–98%
1–95%
0.2–80%
1–14%

31–98%
1–96%
3–70%
1–51%

0.49–2.65
0.63–2.20
0.48–18.09
0.24–4.02

0.006
0.20
<0.001
0.07

Table 4 | Variation in bleeding avoidance strategy use and effect of personalized
bleeding risk estimates across physicians
Median odds ratios across all
hospitals

Median odds ratios within
hospitals

Bleeding avoidance strategy

Pre-PRISM

Post-PRISM

Pre-PRISM

Post-PRISM

Any strategy
Bivalirudin
Closure device
Radial access

9.4
11.0
7.9
3.2

7.8
11.3
6.3
3.3

3.7
3.7
3.5
2.8

4.1
4.5
4.2
2.2

Bivalirudin use (%)

Bleeding risk

6

Before risk stratification

40

2
0
0

100

100

After risk stratification

80
60
40
20
0
0

0.02

0.04

0.06

0.08

0.10

Bleeding risk

Fig 2 | Individual physicians’ variability in use of
bivalirudin, as a function of bleeding risk, before and after
PRISM. Each line represents a physician in the study

Discussion
To our knowledge, this is the first demonstration that
precision medicine, delivered through pre-procedural
risk stratification, can improve the safety of medical care
by supporting tailored treatment in patients at the greatest risk for adverse outcomes. In this before/after study at
nine US percutaneous coronary intervention centers, we
sought to overcome a well documented risk-treatment
paradox in healthcare delivery by prospectively providing personalized estimates of bleeding risk for patients
undergoing percutaneous coronary intervention. This
intervention was associated with increased use of bleeding avoidance strategies overall, with a greater use in
high risk patients (odds ratio 1.41) after adjustment for
contemporary trends in bleeding management. The only
other change in anticoagulation regimens observed at
the intervention sites, compared with control sites, was a
lower use of low molecular weight heparins, which have
been associated with less bleeding and may have diminished the observed differences in bleeding between intervention and control sites. Most importantly, the overall
bleeding rates improved significantly more at the intervention sites after prospective risk stratification than was
observed at other matched hospitals participating in the
NCDR registry (reduction in odds of bleeding at intervention sites 44% v 9% at control sites). These findings
extend our previous experience at a single institution to
support the generalizability of this approach.34
Implications of findings
This study highlights the potential value of risk models
to improve care. Although risk adjusted benchmarking
of performance can enable hospitals to identify whether
they are performing favorably compared with their
doi: 10.1136/bmj.h1302 | BMJ 2015;350:h1302 | the bmj
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peers, we are unaware of any examples in which these
models have been prospectively used to improve medical decision making. In the case of percutaneous coronary intervention related bleeding, the CathPCI Registry
data enabled researchers to create a risk model to predict bleeding,26 determine that bleeding avoidance
strategies were preferentially used in patients at the
lowest risk and with the least potential to benefit,22 and
prospectively use that model to support more efficient,
evidence based medical decision making and safer
care. Many additional opportunities exist to update the
risk models with emerging risk factors and extend this
concept to other medical disciplines.35
This study also highlights extraordinary variability in
care by both hospitals and physicians within hospitals.
For example, the use of bivalirudin varied from 1% to
95% across the nine centers in this study, with an 11-fold
difference in the likelihood that two patients with identical characteristics treated by one random physician versus another would be treated with the drug. Even within
the same hospital, a fourfold variation in bivalirudin use
existed across providers, after adjustment for risk of
bleeding and patients’ other characteristics. For example, few people would argue that a patient with a very
high, 10% risk of bleeding should not be treated with at
least one bleeding avoidance strategy. In this study, we
found that the likelihood of such a patient receiving any
bleeding avoidance strategy ranged from 1% to 100%,
depending on which interventionalist performed the
procedure. Decreasing such variability in care based on
physicians’ preferences, rather than patients’ benefits,
represents an important opportunity to improve quality
and outcomes. Given that the provision of prospective,
individualized bleeding risk estimates had little effect on
the observed variability in care, we believe that future
efforts to support more consistent care may require
implementation of clear protocols for optimal use of
bleeding avoidance strategies as a function of bleeding
risk, feedback reports on protocol adherence, and holding physicians accountable for their practice patterns.36

Limitations of study
Our findings should be interpreted in the context of several potential limitations. Firstly, this was a non-randomized study with a before/after design. Because we
changed the processes of obtaining informed consent,
we could not randomize individual patients. A cluster
randomized study design would have more definitively
compared the effect of pre-procedural risk stratification
on care and outcomes. Nevertheless, we were able to
leverage the same data collection infrastructure at more
than 1100 hospitals to document a significantly greater
reduction in bleeding compared with contemporary
trends. We were also able to use propensity models to
ensure that patients in the pre-intervention phase were
similar to those in the post-intervention time period.
Secondly, the inclusion of nine sites limits the generalizability of the findings to other institutions. Our findings are also not generalizable to ST elevation
myocardial infarction or emergent patients, as these
emergency cases were excluded from our study.
the bmj | BMJ 2015;350:h1302 | doi: 10.1136/bmj.h1302

 owever, the lessons learnt from this effort, particularly
H
our belief in the importance of having established protocols and feedback, could potentially lead to more successful future implementations.
A third limitation is that the optimal management of
anticoagulation and antiplatelet treatment at the time of
percutaneous coronary intervention is complex,37 with
both oral (for example, clopidogrel, aspirin) and intravenous (glycoprotein IIb/IIIa) antiplatelet agents and a
range of anticoagulants (bivalirudin, unfractionated
and low molecular weight heparin) used in various combinations by different operators. We were unable to attribute the reduction in bleeding solely to the observed
changes in use of bleeding avoidance strategies. However, this does not detract from the importance of our
finding that prospective risk stratification was associated with improved bleeding outcomes for patients
undergoing percutaneous coronary intervention, however it was achieved. An additional concern might be the
recently announced results of the HEAT PPCI study, in
which bivalirudin did not result in less bleeding than
heparin alone.38 We excluded primary percutaneous coronary intervention from our analyses, and our results
should not be affected by this new information. A further potential concern is the short time of observation
after pre-procedural risk stratification was introduced
and that physicians might take a longer time to incorporate such information into their practice patterns, something that would have led to underestimation of the
potential benefits of this approach. Finally, the bleeding
events were not independently adjudicated, with reliance on the NCDR data collection infrastructure, and we
were not able to adjudicate ischemic complications that
may have been affected by changes in antithrombotic
treatment. We also did not have long term outcomes
available, and nor were we able to compare the accuracy
of bleeding events in NCDR between our nine centers
and the rest of the NCDR. Future work should attempt to
assess these outcomes more definitely.
The Institute of Medicine has challenged US healthcare
to be more patient centered, evidence based, and efficient, as well as safer.11 We have previously reported that
the enhanced informed consent documents generated by
the personalized consents improved patients’ experiences with consent to percutaneous coronary intervention.39 In this study, we have shown that prospective,
individualized bleeding risk estimates were associated
with more appropriate use of bleeding avoidance strategies and significantly lower bleeding rates. Nevertheless,
the variability of care observed in this study suggests an
important opportunity to further improve the safety and
quality of percutaneous coronary intervention care.
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